Scrip
Poniard plunges after picoplatin fails pivotal lung cancer trial
17 November 2009
Malini Guha
Please Login to read the full article.
17 November 2009
Malini Guha
Malini.guha@informa.com
Poniard Pharmaceuticals' only drug candidate in clinical development, the chemotherapeutic agent picoplatin, has failed to improve overall survival in its pivotal Phase III SPEAR trial in the second-line treatment of small cell lung cancer (SCLC), leading its shares to plunge by over 75% on Nasdaq...
Please Login to read the full article.
RELATED CONTENT
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Face-to-Face: Trophos looks to nourish ALS market with olesoxime
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
